ReviewSports medicine (Auckland, N.Z.)2017
Biological Therapies in Regenerative Sports Medicine.
Review in Sports medicine (Auckland, N.Z.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- The impact of platelet-rich plasma injection on anterior cruciate ligament reconstruction: a systematic review and meta-analysis.Frontiers in bioengineering and biotechnology · 2025Pooled it
- Platelet-rich plasma (PRP) augmentation does not result in more favourable outcomes in arthroscopic meniscal repair: a meta-analysis.Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology · 2022Pooled it
- Mesenchymal Stem Cells for Treatment of Tendon and Ligament Injuries-clinical Evidence.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2020Pooled it
- Freeze-Drying of Platelet-Rich Plasma: The Quest for Standardization.International journal of molecular sciences · 2020Pooled it
- The efficacy and safety of platelet-rich fibrin for rotator cuff tears: a meta-analysis.Journal of orthopaedic surgery and research · 2018Pooled it
- Adjuvant Biological Therapies in Chronic Leg Ulcers.International journal of molecular sciences · 2017Pooled it
- Intra-articular platelet-rich plasma vs corticosteroids in the treatment of moderate knee osteoarthritis: a single-center prospective randomized controlled study with a 1-year follow up.Journal of orthopaedic surgery and research · 2020Trial
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports medicine (Auckland, N.Z.) · 2026Review
- Primary versus rerupture of the anterior cruciate ligament: rupture site patterns and graft elongation-a systematic review and meta-analysis.Knee surgery & related research · 2026Review
- Lateral and posterolateral iliac crest approach for bone marrow aspirate harvest in regenerative orthopedic applications.Journal of orthopaedic surgery and research · 2026Article
- Engineering Regenerative Fibrin Scaffold from Balanced Protein-Concentrate Plasma: Structural and Biochemical Characterization.Pharmaceutics · 2025Article
- Therapeutic Potential of Mesenchymal Stem Cell and Tenocyte Secretomes for Tendon Repair: Proteomic Profiling and Functional Characterization In Vitro and In Ovo.International journal of molecular sciences · 2025Article
- Hierarchy Reproduction: Multiphasic Strategies for Tendon/Ligament-Bone Junction Repair.Biomaterials research · 2025Review
- Biologically Enhanced Patch in the Healing and Mechanical Stability of Rotator Cuff Tears.Journal of biotechnology and biomedicine · 2024Article
- Cartilage fragments combined with BMSCs-Derived exosomes can promote tendon-bone healing after ACL reconstruction.Materials today. Bio · 2023Article
- Bibliometric and visualization analysis of stem cell therapy for meniscal regeneration from 2012 to 2022.Frontiers in bioengineering and biotechnology · 2023Article
- Cartilaginous Metabolomics Reveals the Biochemical-Niche Fate Control of Bone Marrow-Derived Stem Cells.Cells · 2022Article
- Meniscus repair: up-to-date advances in stem cell-based therapy.Stem cell research & therapy · 2022Review
- Upregulation of Runt related transcription factor 1 (RUNX1) contributes to tendon-bone healing after anterior cruciate ligament reconstruction using bone mesenchymal stem cells.Journal of orthopaedic surgery and research · 2022Article
- Attenuation of osteoarthritis progression through intra-articular injection of a combination of synovial membrane-derived MSCs (SMMSCs), platelet-rich plasma (PRP) and conditioned medium (secretome).Journal of orthopaedic surgery and research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regenerative medicine seeks to harness the potential of cell biology for tissue replacement therapies, which will restore lost tissue functionality. Controlling and enhancing tissue healing is not just a matter of cells, but also of molecules and mechanical forces. We first describe the main biological technologies to boost musculoskeletal healing, including bone marrow and subcutaneous fat-derived regenerative products, as well as platelet-rich plasma and conditioned media. We provide some information describing possible mechanisms of action. We performed a literature search up to January 2016 searching for clinical outcomes following the use of cell therapies for sports conditions, tendons, and joints. The safety and efficacy of cell therapies for tendon conditions was examined in nine studies involving undifferentiated and differentiated (skin fibroblasts, tenocytes) cells. A total of 54 studies investigated the effects of mesenchymal stem-cell (MSC) products for joint conditions including anterior cruciate ligament, meniscus, and chondral lesions as well as osteoarthritis. In 22 studies, cellular products were injected intra-articularly, whereas in 32 studies MSC products were implanted during surgical/arthroscopic procedures. The heterogeneity of clinical conditions, cellular products, and approaches for delivery/implantation make comparability difficult. MSC products appear safe in the short- and mid-term, but studies with a long follow-up are scarce. Although the current number of randomized clinical studies is low, stem-cell products may have therapeutic potential. However, these regenerative technologies still need to be optimized.
Indexed as
Identifiers
27677916What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.